A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 671
- Population
- ALL · 50 Years
- Duration
- 2019-02-19 to 2022-01-18
- Intervention
- Faricimab; Aflibercept; Sham Procedure
- Comparator
- Aflibercept
- Outcomes measured
- Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — From Baseline through Week 48; Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 — From Baseline through Week 60; Change From Baseline in BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48,…; Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the…; Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and…; Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…; Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…; Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…; Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…; Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged…; Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 5…; Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…; Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…; Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…; Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or…; Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged…; Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Tim…; Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged…; Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Tim…; Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.